Axitinib: Optimizando el tratamiento de segunda línea del cáncer renal - page 7

Second‐line agents in mRCC (A–Z)
Cabozantinib2† Everolimus 3† Axitinib1*
Nivolumab5 ‡ Sorafenib6§ Lenvatinib +
li 4† evero mus
1. Inlyta ® SmPC 2016; 2. Cabometyx® SmPC 2016; 3. Afinitor® SmPC 2016; 4. Kisplyx® SmPC 2016; 5. Opdivo ® SmPC 2016; 6. Nexavar® SmPC 2015
*Approved in advanced RCC after sunitinib or cytokine therapy;†Approved in advanced RCC after prior VEGF‐targeted therapy;‡Approved in RCC
after prior therapy;§Approved as an option in first‐line advanced RCC, after IFN‐α/IL‐2 or if unsuitable for IFN‐α/IL‐2